Regrese osteolytického loziska u pacienta s mnohocetným myelomem léceného klodronátem po uspesné terapii rezimem s bortezomibem [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen]

Details

Serval ID
serval:BIB_3C3FAA48E717
Type
Article: article from journal or magazin.
Collection
Publications
Title
Regrese osteolytického loziska u pacienta s mnohocetným myelomem léceného klodronátem po uspesné terapii rezimem s bortezomibem [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen]
Journal
Klinicka onkologie
Author(s)
Szturz Petr, Jakubcová R., Adam Z., Klincová M., Krejcí M., Pour L., Zahradová L., Hájek R., Mayer J.
ISSN
0862-495X (Print)
ISSN-L
0862-495X
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
24
Number
3
Pages
216-220
Language
Czech
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Abstract
Osteolytic lesions are a common manifestation of multiple myeloma, though their healing is rare in these patients. Generally, during a complete remission, lesions only stop progressing; radiologically evident recalcification is exceptional.
Herein we report a case of a male patient born in 1941 and diagnosed in 2005 with IgA multiple myeloma presenting with multiple osteolytic bone lesions. Administration of 4 cycles of VAD chemotherapy (vincristine, adriamycin, dexamethasone) with subsequent autologous peripheral blood stem cell transplantation and maintenance treatment with interferon alpha had resulted into a very good partial remission. In 2009, the disease relapsed with enlargement of osteolytic lesions evident on skiagrams. The largest lesion, reaching 24 x 10 mm in size, was located in the left femur. A complete remission of the disease was achieved with CVD senior regimen (cyclophosphamide, bortezomib, dexamethasone, 8 cycles in total). Bisphosphonates (zoledronate, ibandronate and, from 2007, clodronate) were administered as a long-term supportive therapy. A one-year follow-up skiagram of the left femur revealed over 50% regression of the osteolytic lesion (10 x 5 mm) documented in a set of pictures herein.
A complete remission of the disease after an administration of bortezomib (Velcade)-based regimen in a long-term clodronate (Bonefos)-treated patient with relapsed multiple myeloma is radiographically apparent by clear healing signs of the osteolytic bone lesion.
Keywords
Aged, Antineoplastic Agents/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Bone Density Conservation Agents/therapeutic use, Boronic Acids/administration & dosage, Bortezomib, Clodronic Acid/therapeutic use, Femur/diagnostic imaging, Humans, Male, Multiple Myeloma/complications, Multiple Myeloma/diagnostic imaging, Multiple Myeloma/drug therapy, Multiple Myeloma/pathology, Osteolysis/complications, Osteolysis/diagnostic imaging, Osteolysis/drug therapy, Pyrazines/administration & dosage, Radiography, Recurrence, Remission Induction
Pubmed
Create date
07/01/2025 17:11
Last modification date
08/01/2025 7:04
Usage data